egfrin8

EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC.

EGFR-IN-87 is a potent EGFR tyrosine kinase inhibitor with anticancer activity that inhibits EGFR_d746-750, EGFR_L858R/T790M, and EGFR_WT in A431 cells, and can be used for cancer research.

EGFR-IN-87 (Compound Example 2) hydrochloride is an EGFR tyrosine kinase inhibitor. It has IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM for EGFR_d746-750, EGFR_L858R/T790, and EGFR_WT, respectively, in A431 cells. EGFR-IN-87 hydrochloride is useful for cancer research.

EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR signaling. It is utilized in Glioblastoma (GBM) research [1].

EGFR-IN-86 (compound 4i), an EGFR inhibitor (IC50: 1.5 nM), demonstrates potent activity against glioblastoma by inducing apoptosis and causing G2/M phase cell cycle arrest in U87 cells [1].

EGFR-IN-81 (Compound 10i), an EGFR inhibitor, demonstrates potent activity by inhibiting EGFR WT and the L858R/T790M mutation at IC50 values of 4.38 nM and 5.69 nM, respectively. It also exhibits cytotoxic effects against MCF-7 and HCT116 cell lines with IC50 values of 2.07 μM and 6.72 μM, respectively [1].

EGFR-IN-84 (Compound 6g), an EGFR inhibitor with an IC50 of 24 nM, impedes the growth of A549 cells with an IC50 value of 1.537 μM and is utilized for lung cancer research [1].

EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50 values of 2.50 μM and 1.96 μM. Furthermore, EGFR-IN-83 is capable of inducing cell apoptosis [1].

EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosis [1].

EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor that selectively targets EGFR mutations, showing potent activity with an IC50 of 10.1 nM against Del19/T790M/C797S mutations, and demonstrating greater selectivity for mutant forms over wild type [1].